Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 4

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 4
---
 or not contingent, of the Company and its subsidiaries related solely to any product candidate of the Company and its subsidiaries, other than the Company’s Dual Orexin Agonist platform (“DOXA”). It is expected that the proceeds from any such disposition will be distributed pursuant to the terms and conditions of a contingent value rights agreement, substantially in the form attached to the Merger Agreement and as Exhibit 4.2 to the registration statement of which this proxy statement/prospectus forms a part (the “CVR Agreement”) to the holders of NLS Common Stock (as defined in the CVR Agreement), the holders Preferred Shares (as defined in the CVR Agreement), the holders Preferred Certificates (as defined in the CVR Agreement), and the holders of warrants and pre -fundedwarrants of the Company, in each as of immediately prior to the Effective Time (such holders collectively, the “CVR Recipients”), subject to the adjustments set forth in the CVR Agreement. NLS’s officers (other than Mr. Konofal who shall remain in a part -timeposition with NLS) and members of the NLS board of directors (the “NLS Board”), will resign as of the Effective Time and it is anticipated that Kadimastem’s executive officers and members of its board of directors (the “Kadimastem Board”), as of the Effective Time will become NLS’s executive officers and members of the NLS Board; provided, however, that Mr. Alexander Zwyer shall not resign as a member of the NLS Board at the Effective Time and shall remain as a member of the NLS Board and, from the date of the Closing, until the date that is one year after the date of the Closing, the combined company shall not take any action to remove, or recommend the removal of Mr.Zwyer from the combined company’s board of directors without cause, and shall nominate for election and continue to recommend to its shareholders that Mr.Zwyer be elected to serve as a director of the combined company. As a condition to his continued service and re -appointment, Mr.Zwyer shall tender an irrevocable resignation letter effective upon the lapse of one year from the date of the Closing, subject to acceptance of his resignation by the NLS Board. At the Effective Time, each: •Kadimastem Ordinary Share issued and outstanding immediately prior to the Effective Time will be exchanged for and converted into the right to receive a number of newly issued, fully paid and nonass